雌激素受体和免疫检查点抑制剂：肺癌的新伴侣？
Estrogen receptor and immune checkpoint inhibitors: new partners in lung cancer?
发表日期：2023 Aug 07
作者：
Karmele Valencia, Luis M Montuenga, Alfonso Calvo
来源：
Immunity & Ageing
摘要：
关于非小细胞肺癌(NSCLC)患者免疫治疗反应受性别影响的研究尚未得出明确结论。本期文章报道了一个关键结果，表明影响治疗反应的因素并非性别，而是NSCLC中17-β-雌二醇/ERα/PDL1信号传导环路的存在。这一有趣的发现为开展新的治疗选项打开了大门。
The influence of sex on immunotherapy response in NSCLC patients had been studied with no clear conclusions. An article in this issue reports that a key determinant of response is not sex but the existence of a 17-β-estradiol/ERα/PDL1 signaling loop in NSCLC. This intriguing result opens new therapeutic options.